Rabbani et al.

Serial No.: 08/978,635

Filed: November 25, 1997

Page 3 [Response To The October 23, 2003 Notice Of Non-Compliant Amendment

FEB 0 9 200

(37 CFR 1.121) - November 5, 2003]

AMEND THE ABOVE-IDENTIFIED APPLICATION AS FOLLOWS:

CLAIM AMENDMENTS

1-244 (cancelled)

245 (currently amended) A process for selectively expressing a nucleic acid product into one or more compatible cells, which product requires processing for functioning, said process comprising;

- providing a nucleic acid construct which when introduced into said cells produces a nucleic acid product comprising a non-native intron, which when in one or more compatible cells, said processing element is substantially removed from the nucleic acid product during processing of the nucleic acid product and
- (ii) introducing said construct into said compatible cells.

Claim 246 is cancelled.

247. (previously amended) The process of claim 245, wherein said nucleic acid product is selected from the group consisting of antisense RNA, antisense DNA, sense RNA, sense DNA, a ribozyme and a protein binding nucleic acid sequence and a combination of the foregoing.

248. (currently amended) The process of claim 245, wherein said construct is introduced ex vivo into said cells.

Rabbani et al.

Serial No.: 08/978,635

Filed: November 25, 1997

Page 4 [Response To The October 29, 2003 Notice Of Non-Compliant Amendment

(37 CFR 1.121) - November 5, 2003]

249. (currently amended) The process of claim245, wherein said construct is introduced in vivo into said cells.

250. (currently amended) The process of claim 245, wherein said construct is introduced into a biological system containing said cells.

251. (previously amended) The process of claim 250, wherein the biological system is selected from the group consisting of an organism, an organ, a tissue and a culture or a combination of the foregoing.

252. (new) The method according to claim 245, wherein said non-native intron is in a coding sequence of said nucleic acid product.